STTR Phase I: Rapid-Release Cell Culture Platform for Flow Cytometry

STTR 第一阶段：用于流式细胞术的快速释放细胞培养平台

• 批准号: 2126903
• 负责人: Michael Cross
• 金额: $ 25.55万
• 依托单位: CROSSMHV, L.L.C
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2126903&HistoricalAwards=false
• 关键词: STTR; Phase; Rapid; Release; Cell

The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to enable new health diagnostics, advance personalized medicine, and accelerate research for various diseases, including many types of cancers. Many methods used to diagnose disease are limited by the methods used to process patient samples. Commonly used processes can disrupt or destroy disease markers present in samples, leading to concerns about diagnostic dependability and accuracy. The proposed product platform can address this pain point by retaining disease markers as well as increasing yields which results in higher-fidelity experimental results and ultimately, enhances diagnostic medicine.The proposed project will advance the development of a transformational biotechnology platform which non-destructively detaches adherent mammalian cells from a cell dish surface. Existing methods can damage these cells and are highly varied in cell yields which greatly limit clinical applications for disease diagnosis and therapeutic discovery. To fulfill its promise as a highly compelling alternative to existing methods, the following technical hurdles will be addressed in this project: 1) determining the optimal composition and design of the material, 2) validating the effects of the platform on cells, 3) using fabrication methods conducive to manufacturing purposes, and 4) benchmarking its performance against existing Flow Cytometry methods for adherent cells.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这种小型企业技术转移（STTR）I期项目的更广泛影响是启用新的健康诊断，预先的个性化医学以及加速各种疾病（包括许多类型的癌症）的研究。用于诊断疾病的许多方法受到处理患者样品的方法的限制。常用的过程可能会破坏或破坏样本中存在的疾病标志物，从而担心诊断性可靠性和准确性。提出的产品平台可以通过保留疾病标志物以及增加产量来解决这个疼痛点，从而导致更高的实验结果，并最终增强诊断医学。拟议的项目将推动发展转化的生物技术平台的发展，该平台非破坏性地从细胞盘中脱离了粘附的哺乳动物细胞。现有方法会损害这些细胞，并且细胞产量高度不同，这极大地限制了疾病诊断和治疗性发现的临床应用。为了履行其作为现有方法的高度令人信服的替代方案的诺言，该项目将解决以下技术障碍：1）确定材料的最佳组成和设计，2）验证平台对单元的影响，3）使用制造方法，使用制造目的，以及4）对现有的统计范围的统计范围进行了统计，并将其用于ADSTORMENTRED STATERSS的绩效。值得通过基金会的智力优点和更广泛的影响审查标准来通过评估来支持。